# Adial Pharmaceuticals Inc (ADIL)

Source: https://www.quantisnow.com/company/ADIL
Generated: 2026-11-08T09:23:31.933Z

- Ticker: ADIL
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2018
- SEC CIK: 0001513525
- Website: adialpharma.com

## About

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.

## Latest ADIL news and filings

- 2026-11-05 12:00 UTC [Leadership Update] [Azora Therapeutics Appoints Board of Directors with Extensive Drug Development and Inflammatory Bowel Disease Expertise](https://www.quantisnow.com/insight/azora-therapeutics-appoints-board-of-directors-with-extensive-drug-development-6774385)
- 2026-10-31 00:44 UTC [SEC Form 4] [SEC Form 4 filed by Adial Pharmaceuticals Inc](https://www.quantisnow.com/insight/sec-form-4-filed-by-adial-pharmaceuticals-inc-6765746)
- 2026-10-31 00:36 UTC [SEC Form 3] [SEC Form 3 filed by Adial Pharmaceuticals Inc](https://www.quantisnow.com/insight/sec-form-3-filed-by-adial-pharmaceuticals-inc-6765745)
- 2026-10-31 00:35 UTC [SEC Form 3] [SEC Form 3 filed by Adial Pharmaceuticals Inc](https://www.quantisnow.com/insight/sec-form-3-filed-by-adial-pharmaceuticals-inc-6765744)
- 2026-10-28 20:30 UTC [SEC Form 8-K] [SEC Form 8-K filed by Adial Pharmaceuticals Inc](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-adial-pharmaceuticals-inc-6761629)
- 2026-10-28 20:02 UTC [Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis](https://www.quantisnow.com/insight/adial-pharmaceuticals-announces-name-change-to-azora-therapeutics-and-new-6761123)
- 2026-10-27 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Adial Pharmaceuticals Inc](https://www.quantisnow.com/insight/sec-form-effect-filed-by-adial-pharmaceuticals-inc-6758236)
- 2026-10-26 12:00 UTC [Leadership Update] [Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer](https://www.quantisnow.com/insight/adial-pharmaceuticals-announces-planned-appointment-of-celia-economides-as-chief-6757026)
- 2026-10-21 00:25 UTC [SEC Form 10-Q] [Amendment: SEC Form 10-Q/A filed by Adial Pharmaceuticals Inc](https://www.quantisnow.com/insight/amendment-sec-form-10-qa-filed-by-adial-pharmaceuticals-inc-6752676)
- 2026-10-20 23:53 UTC [SEC Form S-3] [Amendment: SEC Form S-3/A filed by Adial Pharmaceuticals Inc](https://www.quantisnow.com/insight/amendment-sec-form-s-3a-filed-by-adial-pharmaceuticals-inc-6752671)
- 2026-10-16 21:16 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Adial Pharmaceuticals Inc](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-adial-pharmaceuticals-inc-6749513)
- 2026-10-16 21:15 UTC [SEC Form 8-K] [SEC Form 8-K filed by Adial Pharmaceuticals Inc](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-adial-pharmaceuticals-inc-6749508)
- 2026-10-16 11:00 UTC [Leadership Update] [Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis](https://www.quantisnow.com/insight/adial-pharmaceuticals-appoints-david-rubenstein-md-phd-as-chief-scientist-6748633)
- 2026-10-02 20:16 UTC [SEC Form 8-K] [Adial Pharmaceuticals Inc filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/adial-pharmaceuticals-inc-filed-sec-form-8-k-other-events-6734592)
- 2026-09-30 21:46 UTC [Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/adial-pharmaceuticals-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-6731028)
- 2026-09-21 23:25 UTC [SEC Form 4] [SEC Form 4 filed by Director Young Wendy B.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-young-wendy-b-6722134)
- 2026-09-18 21:18 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Adial Pharmaceuticals Inc](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-adial-pharmaceuticals-inc-6720842)
- 2026-09-18 20:27 UTC [SEC Form 8-K] [Adial Pharmaceuticals Inc filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/adial-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-submission-6720644)
- 2026-09-16 21:29 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Adial Pharmaceuticals Inc](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-adial-pharmaceuticals-inc-6717985)
- 2026-09-16 21:08 UTC [SEC Form 8-K] [Adial Pharmaceuticals Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement](https://www.quantisnow.com/insight/adial-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-6717917)
- 2026-08-28 20:49 UTC [SEC Form S-3] [SEC Form S-3 filed by Adial Pharmaceuticals Inc](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-adial-pharmaceuticals-inc-6698588)
- 2026-08-28 20:47 UTC [SEC Form S-8] [SEC Form S-8 filed by Adial Pharmaceuticals Inc](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-adial-pharmaceuticals-inc-6698581)
- 2026-08-25 20:33 UTC [SEC Form 8-K] [Adial Pharmaceuticals Inc filed SEC Form 8-K: Unregistered Sales of Equity Securities](https://www.quantisnow.com/insight/adial-pharmaceuticals-inc-filed-sec-form-8-k-unregistered-sales-of-6694435)
- 2026-08-25 20:05 UTC [Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/adial-pharmaceuticals-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-6694146)
- 2026-08-24 20:05 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Adial Pharmaceuticals Inc](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-adial-pharmaceuticals-inc-6692675)
- 2026-08-21 21:17 UTC [SEC Form 8-K] [Adial Pharmaceuticals Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/adial-pharmaceuticals-inc-filed-sec-form-8-k-notice-of-delisting-6691705)
- 2026-08-17 11:17 UTC [SEC Form 8-K] [Adial Pharmaceuticals Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/adial-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-6684199)
- 2026-08-17 11:00 UTC [Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update](https://www.quantisnow.com/insight/adial-pharmaceuticals-reports-2026-second-quarter-financial-results-and-provides-6684145)
- 2026-08-13 21:25 UTC [SEC Form 8-K] [Adial Pharmaceuticals Inc filed SEC Form 8-K: Leadership Update, Other Events](https://www.quantisnow.com/insight/adial-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-other-6681326)
- 2026-08-11 01:17 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Adial Pharmaceuticals Inc](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-adial-pharmaceuticals-inc-6674714)
- 2026-08-11 01:13 UTC [SEC Form 8-K] [Amendment: Adial Pharmaceuticals Inc filed SEC Form 8-K: Financial Statements and Exhibits](https://www.quantisnow.com/insight/amendment-adial-pharmaceuticals-inc-filed-sec-form-8-k-financial-statements-6674711)
- 2026-08-03 12:52 UTC [Analyst Coverage Initiated] [Alliance Global Partners initiated coverage on Adial Pharmaceuticals with a new price target](https://www.quantisnow.com/insight/alliance-global-partners-initiated-coverage-on-adial-pharmaceuticals-with-a-6658965)
- 2026-07-16 21:08 UTC [Insider Buy] [Large owner Coastlands Capital Lp bought $8,691 worth of shares (3,233 units at $2.69) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-coastlands-capital-lp-bought-8691-worth-of-shares-6640092)
- 2026-07-13 14:30 UTC [Insider Buy] [Large owner Coastlands Capital Lp bought $32,638 worth of shares (11,753 units at $2.78) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-coastlands-capital-lp-bought-32638-worth-of-shares-6635089)
- 2026-07-01 14:30 UTC [Insider Buy] [Large owner Coastlands Capital Lp bought $65,000 worth of shares (25,000 units at $2.60) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-coastlands-capital-lp-bought-65000-worth-of-shares-6622298)
- 2026-06-29 16:47 UTC [SEC Form 3] [New insider Coastlands Capital Lp claimed ownership of 348,322 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-coastlands-capital-lp-claimed-ownership-of-348322-shares-6618675)
- 2026-06-16 12:00 UTC [Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing](https://www.quantisnow.com/insight/adial-pharmaceuticals-expands-executive-leadership-team-and-closes-pipe-financing-6603923)
- 2026-06-16 10:36 UTC [SEC Form 4] [Chief Development Officer Davidson Matt was granted 297,491 shares and was granted 1,923 units of Series A Preferred Stock (SEC Form 4)](https://www.quantisnow.com/insight/chief-development-officer-davidson-matt-was-granted-297491-shares-and-6603783)
- 2026-06-16 10:35 UTC [SEC Form 3] [SEC Form 3 filed by new insider Davidson Matt](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-davidson-matt-6603781)
- 2026-06-16 10:14 UTC [SEC Form 4] [SEC Form 4 filed by Director Young Wendy B.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-young-wendy-b-6603756)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ADIL
- Earnings history: https://www.quantisnow.com/earnings/ADIL
- Dividend history: https://www.quantisnow.com/dividends/ADIL
- Insider transactions: https://www.quantisnow.com/insiders/ADIL
- Options chain: https://www.quantisnow.com/options/ADIL
- SEC 8-K filings only: https://www.quantisnow.com/company/ADIL/8-k
- RSS and alerts for ADIL: https://www.quantisnow.com/docs/rss-feeds.md